-
Mubritinib (TAK 165) in Mitochondrial Oncology
2026-09-15
Mubritinib redirects HER2-oriented research toward mitochondrial complex I, oxidative phosphorylation, and ROS-dependent cell death. This workflow shows how to evaluate TAK 165 alone or with cisplatin in NSCLC while extending the strategy to AML and primary effusion lymphoma models.
-
IGFBP2–THBS1 Axis in Growth Hormone Therapy
2026-09-15
The reference study identifies an IGFBP2–THBS1 regulatory axis that connects growth hormone exposure with IGF-1-associated chondrocyte proliferation and hypertrophic differentiation in idiopathic short stature research. Its combination of patient plasma data and gain- and loss-of-function experiments provides a mechanistic framework, while the in vitro design leaves important clinical and in vivo questions unresolved.
-
Nigericin Sodium Salt: Protocol and QC Guide
2026-09-14
Nigericin sodium salt is a potassium ionophore for controlled K+ and H+ exchange, supporting membrane ion-transport, cytoplasmic pH, platelet, and selected Pb2+ transport assays. It should be used as an ethanol-solubilized research reagent, not in aqueous or DMSO-based workflows, long-term stored working solutions, diagnostic testing, or medical treatment.
-
Psoralen-Induced Cholestasis via ERK1/2
2026-09-14
Chen and colleagues showed that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through disrupted bile-acid regulation and increased ERK1/2 phosphorylation. The study connects phytoestrogen exposure to a defined signaling mechanism and supports ERK1/2 inhibition as an experimental strategy for dissecting estrogen-induced cholestasis.
-
C. auris Virulence: From Biology to Cell Readouts
2026-09-13
A translational framework for connecting clade-specific resistance and virulence in Candidozyma auris with reproducible cell-based measurements. The article explains where Crystal Violet Staining Solution can strengthen host-cell, migration, invasion, proliferation, and colony-based workflows while clarifying its limits as a research readout rather than a diagnostic or direct antifungal susceptibility test.
-
Clathrin-Mediated Entry of Type III GCRV
2026-09-12
Wang et al. used pharmacological inhibitors, transmission electron microscopy, and quantitative PCR to define how genotype III grass carp reovirus enters grass carp kidney cells. Their results support a dynamin-dependent, pH-sensitive clathrin-mediated endocytic route and identify signaling components that may influence infection, while also illustrating the limits of inhibitor-based pathway assignment.
-
TRPV1+ Nerve Stimulation Suppresses Inflammation
2026-09-12
Song et al. show that targeted activation of TRPV1+ peripheral sensory nerves can suppress systemic inflammation through coordinated somatic, autonomic, endocrine, and splenic pathways. The study provides a mechanistic framework for evaluating neuro-immune regulation while emphasizing the need to distinguish neural anti-inflammatory effects from direct receptor-mediated immune stimulation.
-
Palbociclib in Gastric Cancer Assembloid Assays
2026-09-11
Palbociclib and PD0332991 provide a mechanistically focused way to study CDK4/6–Rb control in complex tumor models. This article explains how gastric cancer assembloids can reveal stromal effects that conventional cell-cycle assays may miss.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-11
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for controlled studies of CDK9-dependent transcription elongation, P-TEFb activity, and exploratory HIV-1 propagation inhibition. It is not a pan-CDK reagent, universal cytotoxicity control, or substitute for paper-specific validation of therapeutic or antiviral effects.
-
HBoV1 Replication and RNA Processing: DNMT1–NS1 Axis
2026-09-10
The reference study identifies DNMT1-dependent DNA methylation as a regulatory layer in human bocavirus 1 replication and RNA processing. Its central mechanistic finding is that the viral NS1 protein promotes DNMT1 degradation through the ubiquitin–proteasome pathway, shifting the balance from viral DNA synthesis toward productive RNA processing and protein expression.
-
Palmitic acid: Practical Protocol and QC Guide
2026-09-10
This guide explains how to prepare, document, and quality-check Palmitic acid (SKU N2456) for in vitro lipid and metabolic workflows. It is appropriate for defined solvent-based experiments but should not be used where aqueous solubility or long-term storage of prepared solutions is required.
-
Luminescent ATP Cell Viability Assay Kit I Guide
2026-09-09
Use ATP-dependent luciferase luminescence detection to quantify treatment-related viability changes rapidly, including combination effects in ferroptosis models. This workflow guide shows how to apply the Luminescent ATP Cell Viability Assay Kit I to ciprofloxacin–RSL3 studies while separating viability evidence from mechanistic proof.
-
AM251: A Practical CB1 Receptor Antagonist Workflow
2026-09-09
AM251 enables controlled disruption of CB1 signaling in receptor, synaptic, behavioral, metabolic, and cell-cycle assays. This workflow connects nanomolar pharmacology with practical controls, formulation guidance, and troubleshooting for cannabinoid receptor research.
-
Cisapride in iPSC-CM Cardiotoxicity Workflows
2026-09-08
Cisapride (R 51619) combines 5-HT4 receptor agonism with hERG channel inhibition, making it a useful mechanistic stressor for cardiac electrophysiology research. In iPSC-derived cardiomyocyte assays, it can connect high-content morphology, deep-learning phenotypes, and orthogonal electrophysiology for earlier cardiac arrhythmia risk assessment.
-
WQ-C-401 Blocks PDGFR-Driven Pulmonary Remodeling
2026-09-08
The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that reduced pulmonary vascular remodeling, right ventricular pressure, and inflammatory-cell accumulation in a monocrotaline model of pulmonary arterial hypertension. Its combination of kinome profiling, cell-based signaling assays, and in vivo pathology provides a useful framework for evaluating PDGFR-directed therapies beyond established comparator drugs.